ALRN - Aileron Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Aileron Therapeutics, Inc.

490 Arsenal Way
Suite 210
Watertown, MA 02472
United States
617-995-0900
http://www.aileronrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees23

Key Executives

NameTitlePayExercisedYear Born
Dr. Manuel C. AivadoPres, CEO & Director674.13kN/A1970
Dr. Vojislav Vukovic M.D., Ph.D.Sr. VP & Chief Medical Officer536.58kN/A1967
Mr. Richard J. WanstallVP of Fin. & Operations, Principal Financial Officer and Principal Accounting OfficerN/AN/A1968
Dr. D. Allen Annis Ph.D.Sr. VP of ResearchN/AN/A1973
Ms. Kathryn J. Gregory MBASr. VP & Chief Bus. OfficerN/AN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Aileron Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.